- Home
- Publications
- Publication Search
- Publication Details
Title
Specifically targeting ERK1 or ERK2 kills Melanoma cells
Authors
Keywords
-
Journal
Journal of Translational Medicine
Volume 10, Issue 1, Pages 15
Publisher
Springer Nature
Online
2012-01-26
DOI
10.1186/1479-5876-10-15
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression
- (2011) J Lin et al. BRITISH JOURNAL OF CANCER
- Latest developments in the treatment of melanoma: ‘a penicillin moment for cancer’?
- (2011) Spyros Retsas JOURNAL OF THE ROYAL SOCIETY OF MEDICINE
- Biological challenges of BRAF inhibitor therapy
- (2011) Igor Puzanov et al. Molecular Oncology
- Vemurafenib
- (2011) Keith. T Flaherty et al. NATURE REVIEWS DRUG DISCOVERY
- Resistance to BRAF Inhibition in Melanomas
- (2011) David B. Solit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the RAS pathway in melanoma
- (2011) Zhenyu Ji et al. TRENDS IN MOLECULAR MEDICINE
- The “SWOT” of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
- (2011) Moriah H. Nissan et al. Current Oncology Reports
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
- (2010) K H T Paraiso et al. BRITISH JOURNAL OF CANCER
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs
- (2010) C Sheridan et al. ONCOGENE
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Increasing Burden of Melanoma in the United States
- (2009) Eleni Linos et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MAP kinase: It’s been longer than fifteen minutes
- (2008) Thomas W. Sturgill BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Is B-Raf a Good Therapeutic Target for Melanoma and Other Malignancies?
- (2008) S. V. Madhunapantula et al. CANCER RESEARCH
- BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins
- (2008) B. B. Friday et al. CANCER RESEARCH
- Tumour cell survival signalling by the ERK1/2 pathway
- (2008) K Balmanno et al. CELL DEATH AND DIFFERENTIATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started